The Barcelona Science Park (PCB) just opened the call to participate at the 12th edition of BATX2LAB, a tutoring program for secondary school students who undertake research projects. The initiative is part of the Research in Society program -organized by PCB´s Science Outreach Division- that offers around 80 activities addressed at different audiences from a wide age range with a participation of over 4,5000 people each year.
Two translational research studies published in the high impact scientific magazines Journal of Allergy and Clinical Immunology and Journal of Investigative Dermatology have described new immunologic mechanisms in psoriasis, a chronic cutaneous inflammatory disease which affects around the 2% of the population. The studies have been led by Lluís Francesc Santamaria, Director of the group of Translationary Immunology of the University of Barcelona (UB) based at the Barcelona Science Park, together with researchers of the Hospital del Mar and the Municipal Institute for Medical Research, among others.
IDP Pharma, founded in 2015 and with headquarters at the Barcelona Science Park (PCB) has raised, during its first operative year, over 2 million euros from public and private capital. The biopharmaceutical company –specializes in the development of drugs for cancer treatment directed to a new class of therapeutic targets: IDPs– will appoint this capital to continue the preclinical development of their most advanced products: two first-in-class molecules with antitumor activity for Multiple Myeloma, the second most common blood cancer
Mundipharma its independent associated company Purdue Pharma today announced that, following completion of Phase II studies, they have exercised their option and taken over full responsibility from Laboratorios Esteve for the clinical, regulatory and commercial development of a potential first-in-class sigma-1 antagonist (AS1 o MR309/E-52862). In June 2012, Esteve has moved its Center for Drug Discovery and Preclinical Development to the Barcelona Science Park (PCB) in an attempt to shorten development time and speed up the arrival to market of innovative new drugs.
In line with the ground-breaking pay-per-use philosophy, Mind the Byte has launched six new programs for computational drug design on their SaaS platform (Software as a Service), which the company has been marketing since 2011. The new software expands the services currently on offer and helps cut drug-development time and costs up to 30% for companies and researchers. The products were launched at prices that adapt to the needs of each user.
Pharmaphenix –based at the Barcelona Science Park specializing in business development in emergent markets in Latin American and Korea with increasing activity in the Spanish market– has taken part one more year at BIO Korea, the largest partnering conference of the biotech, pharmaceutical and innovation sector in Asia. For three days, the pharmaceutical consultancy firm- with headquarters in Barcelona and in Seoul, South Korea– has intensified its contacts with key actors of the national bio-health sector to consolidate itself as a benchmark partner in the region.
Mind the Byte and Sequentia Biotech, both based at the Barcelona Science Park (PCB), have been two of the 10 Catalan companies that participated last week in a trade mission in the state of Massachusetts (US) to search for business opportunities in the fields of digital health and big data applied to life sciences. The trade mission was organized by the Government of Catalonia through ACCIÓ, the agency for business competitiveness, and Biocat coinciding with Bio-IT World Conference & Expo, one of the largest and most important events in the US in the field of ICTs in the health sector.
A total of 1711 visitors, 580 more than last year, participated in the 2015 Live Research held at CosmoCaixa Barcelona to learn about the leading projects being carried out in eleven research centers and university throughout Catalonia. The fair was organized by the Barcelona Science Park (PCB) and Obra Social ”la Caixa”, with the support of the Barcelona City Council and the collaboration of the University of Barcelona (UB)
Yesterday, 7 April, the Government of Catalonia presented the new TECNIO accreditation in an event led by the Minister of Business and Knowledge, Jordi Baiget, that brought together nearly 300 people from the Catalan scientific and technological community at the Mediapro building. The seal identifies in a first phase 54 entities that offer the most innovative technologies to help business create products, processes or services. Intelligent Pharma, specialized in computational chemistry services for the pharmaceutical and biotechnological industry, based at the Parc Científic de Barcelona, was one of the companies honored to have received this accreditation.
The fourth SciCloud (Scientific Cloud Conference) event held by Mind the Byte, in collaboration with the Barcelona Science Park (PCB) and CataloniaBio, on the 30th of March focused on the innovation models that four emblematic Catalan pharmaceutical companies (Uriach, Ferrer, Kern Pharma and Reig Jofre) use to compete on the global market and on how technology transfer is being successfully promoted through initiatives like Tech & Business Innovation (TBI) and at the Polytechnic University of Valencia.
